Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.

Cancer immunology, immunotherapy : CII - 1 Jun 2013

Fenoglio Daniela, Traverso Paolo, Parodi Alessia, Tomasello Laura, Negrini Simone, Kalli Francesca, Battaglia Florinda, Ferrera Francesca, Sciallero Stefania, Murdaca Giuseppe, Setti Maurizio, Sobrero Alberto, Boccardo Francesco, Cittadini Giuseppe, Puppo Francesco, Criscuolo Domenico, Carmignani Giorgio, Indiveri Francesco, Filaci Gilberto

Abstract excerpt

BACKGROUND: Anti-tumor vaccination is a new frontier in cancer treatment applicable to immunogenic neoplasms such as prostate and renal cancers. GX301 is a vaccine constituted by four telomerase peptides and two adjuvants, Montanide ISA-51 and Imiquimod. OBJECTIVE: The aim of this study was to an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Aminoquinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Cancer Vaccines

Share to Combined Modality Therapy

Share to Cytotoxicity, Immunologic

Share to Mannitol

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 23591981
DOI: 10.1007/s00262-013-1415-9
PMCID: PMC11029691

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23591981-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.PMID 23591981Read ↗

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Clinical research progress of telomerase targeted cancer immunotherapy: a literature reviewSemantic proximity Read ↗

Anti-Cancer Immunotherapies Targeting TelomeraseSemantic proximity Read ↗

Telomerase-based Cancer Therapeutics: A Review on their Clinical TrialsSemantic proximity Read ↗

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapySemantic proximity Read ↗

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Pilot study of p62 DNA vaccine in dogs with mammary tumorsSemantic proximity Read ↗

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.Semantic proximity Read ↗

Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.Semantic proximity Read ↗

Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV Related Liver CancerSemantic proximity Read ↗

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.Semantic proximity Read ↗

Safety and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chemotherapy for the Therapy of Canine B-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.